Skip to main content
. Author manuscript; available in PMC: 2014 May 14.
Published in final edited form as: N Engl J Med. 2013 Nov 14;369(20):1915–1925. doi: 10.1056/NEJMoa1308392

Figure 1. Kaplan–Meier Estimates of Freedom from Disease Progression and Overall Survival.

Figure 1

Panels A and B show the estimates of freedom from progression of disease and overall survival, respectively, among patients who received a dose-adjusted combination of etoposide, doxorubicin, and vincristine with cyclophosphamide, prednisone, and rituximab (DA-EPOCH-R). Panels C and D show the estimates of freedom from progression and overall survival, respectively, among patients who received a short course of the combination therapy with a double dose of rituximab in each cycle (SC-EPOCH-RR). Panels E and F show the estimates of freedom from progression and overall survival, respectively, among patients who had the immunodeficiency-associated variant of Burkitt’s lymphoma.